E-viri
Recenzirano
Odprti dostop
-
Dai, Lianpan; Gao, Lidong; Tao, Lifeng; Hadinegoro, Sri R.; Erkin, Musabaev; Ying, Zhifang; He, Peng; Girsang, Rodman T.; Vergara, Hugo; Akram, Javed; Satari, Hindra I.; Khaliq, Tanwir; Sughra, Ume; Celi, Ana P.; Li, Fangjun; Li, Yan; Jiang, Zhiwei; Dalimova, Dilbar; Tuychiev, Jaloliddin; Turdikulova, Shahlo; Ikram, Aamer; Flores Lastra, Nancy; Ding, Fan; Suhardono, Mahendra; Fadlyana, Eddy; Yan, Jinghua; Hu, Zhongyu; Li, Changgui; Abdurakhmonov, Ibrokhim Y.; Gao, George F.
New England journal of medicine/The New England journal of medicine, 06/2022, Letnik: 386, Številka: 22Journal Article
ZF2001 contains a tandem-repeat dimeric receptor-binding domain of the SARS-CoV-2 spike protein with aluminum hydroxide adjuvant. In a phase 3 trial, 28,904 participants in five countries were randomly assigned to receive three doses of ZF2001 or placebo. After 6 months of follow-up, efficacy was 76% against infection, 87% against critical or severe disease, and 86% against death. Most side effects were local, low-grade, and transient.
